VERTEX PHARMACEUTICALS INC / MA Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax of $1.50 million for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-01.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax · last filed 2020-02-13
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, tax for the quarter ending 2019-03-31 was $1.50M, a 400.00% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, tax for the quarter ending 2018-12-31 was -$7.60M, a 1620.00% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, tax for the quarter ending 2018-09-30 was $0.00, a 100.00% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, tax for the quarter ending 2018-06-30 was $200.00K, a 81.82% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, tax for fiscal 2018 was -$7.10M, a 308.82% decline from fiscal 2017.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, tax for fiscal 2017 was $3.40M.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, tax for fiscal 2016 was -$3.90M.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, tax for fiscal 2015 was $0.00.
| Period end | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax 3 month | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax 3 month as first filed | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax 6 month | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax 6 month as first filed | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax 9 month | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax 9 month as first filed | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax 12 month |
|---|---|---|---|---|---|---|---|
| 2019-03-31 | $1.50M 10-Q · filed 2019-05-01 | -$6.10M derived: sum of 2 quarters · filed 2020-02-13 | -$6.10M derived: sum of 3 quarters · filed 2020-02-13 | -$5.90M derived: sum of 4 quarters · filed 2020-02-13 | |||
| 2018-12-31 | -$7.60M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | -$7.60M derived: sum of 2 quarters · filed 2020-02-13 | -$7.40M derived: sum of 3 quarters · filed 2020-02-13 | -$7.10M 10-K · filed 2020-02-13 | |||
| 2018-09-30 | $0.00 10-Q · filed 2018-10-25 | $200.00K derived: sum of 2 quarters · filed 2018-10-25 | $500.00K 10-Q · filed 2018-10-25 | $1.00M derived: sum of 4 quarters · filed 2020-02-13 | |||
| 2018-06-30 | $200.00K 10-Q · filed 2018-07-26 | $500.00K 10-Q · filed 2018-07-26 | $1.00M derived: sum of 3 quarters · filed 2020-02-13 | $1.90M derived: sum of 4 quarters · filed 2020-02-13 | |||
| 2018-03-31 | $300.00K 10-Q · filed 2019-05-01 | $800.00K derived: sum of 2 quarters · filed 2020-02-13 | $1.70M derived: sum of 3 quarters · filed 2020-02-13 | $2.80M derived: sum of 4 quarters · filed 2020-02-13 | |||
| 2017-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $1.40M derived: sum of 2 quarters · filed 2020-02-13 | $2.50M derived: sum of 3 quarters · filed 2020-02-13 | $3.40M 10-K · filed 2020-02-13 | |||
| 2017-09-30 | $900.00K 10-Q · filed 2018-10-25 | -$900.00K 10-Q · filed 2017-10-30 | $2.00M derived: sum of 2 quarters · filed 2018-10-25 | $2.90M 10-Q · filed 2018-10-25 | -$2.90M 10-Q · filed 2017-10-30 | -$1.40M derived: sum of 4 quarters · filed 2019-02-13 | |
| 2017-06-30 | $1.10M 10-Q · filed 2018-07-26 | -$1.10M 10-Q · filed 2017-07-28 | $2.00M 10-Q · filed 2018-07-26 | -$2.00M 10-Q · filed 2017-07-28 | -$2.30M derived: sum of 3 quarters · filed 2019-02-13 | -$2.50M derived: sum of 4 quarters · filed 2019-02-13 | |
| 2017-03-31 | $900.00K 10-Q · filed 2018-04-27 | -$3.40M derived: sum of 2 quarters · filed 2019-02-13 | -$3.60M derived: sum of 3 quarters · filed 2019-02-13 | -$3.80M derived: sum of 4 quarters · filed 2019-02-13 | |||
| 2016-12-31 | -$4.30M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-13 | -$4.50M derived: sum of 2 quarters · filed 2019-02-13 | -$4.70M derived: sum of 3 quarters · filed 2019-02-13 | -$3.90M 10-K · filed 2019-02-13 | |||
| 2016-09-30 | -$200.00K 10-Q · filed 2017-10-30 | -$400.00K derived: sum of 2 quarters · filed 2017-10-30 | $400.00K 10-Q · filed 2017-10-30 | ||||
| 2016-06-30 | -$200.00K 10-Q · filed 2017-07-28 | $600.00K 10-Q · filed 2017-07-28 | |||||
| 2015-12-31 | $0.00 10-K · filed 2018-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |